These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8742946)
1. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. Calvo P; Vila-Jato JL; Alonso MJ J Pharm Sci; 1996 May; 85(5):530-6. PubMed ID: 8742946 [TBL] [Abstract][Full Text] [Related]
2. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. Calvo P; Alonso MJ; Vila-Jato JL; Robinson JR J Pharm Pharmacol; 1996 Nov; 48(11):1147-52. PubMed ID: 8961163 [TBL] [Abstract][Full Text] [Related]
3. Chitosan based nanocarriers for indomethacin ocular delivery. Badawi AA; El-Laithy HM; El Qidra RK; El Mofty H; El dally M Arch Pharm Res; 2008 Aug; 31(8):1040-9. PubMed ID: 18787795 [TBL] [Abstract][Full Text] [Related]
4. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. De Campos AM; Sánchez A; Gref R; Calvo P; Alonso MJ Eur J Pharm Sci; 2003 Sep; 20(1):73-81. PubMed ID: 13678795 [TBL] [Abstract][Full Text] [Related]
5. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. Miyazaki S; Takahashi A; Kubo W; Bachynsky J; Löebenberg R J Pharm Pharm Sci; 2003; 6(2):238-45. PubMed ID: 12935436 [TBL] [Abstract][Full Text] [Related]
6. Poly(3-hydroxybutyrate-co-epsilon-caprolactone) copolymers and poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-epsilon-caprolactone) terpolymers as novel materials for colloidal drug delivery systems. Pignatello R; Musumeci T; Impallomeni G; Carnemolla GM; Puglisi G; Ballistreri A Eur J Pharm Sci; 2009 Jun; 37(3-4):451-62. PubMed ID: 19504659 [TBL] [Abstract][Full Text] [Related]
7. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Calvo P; Sanchez A; Martinez J; Lopez MI; Calonge M; Pastor JC; Alonso MJ Pharm Res; 1996 Feb; 13(2):311-5. PubMed ID: 8932455 [TBL] [Abstract][Full Text] [Related]
8. In vitro release kinetic pattern of indomethacin from poly(D,L-lactide) nanocapsules. Ammoury N; Fessi H; Devissaguet JP; Puisieux F; Benita S J Pharm Sci; 1990 Sep; 79(9):763-7. PubMed ID: 2273454 [TBL] [Abstract][Full Text] [Related]
9. Alkaline hydrolysis as a tool to determine the association form of indomethacin in nanocapsules prepared with poly(eta-caprolactone). Pohlmann AR; Soares LU; Cruz L; da Silveira NP; Guterres SS Curr Drug Deliv; 2004 Apr; 1(2):103-10. PubMed ID: 16305375 [TBL] [Abstract][Full Text] [Related]
10. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Marchal-Heussler L; Sirbat D; Hoffman M; Maincent P Pharm Res; 1993 Mar; 10(3):386-90. PubMed ID: 8464811 [TBL] [Abstract][Full Text] [Related]
11. Formulation of indomethacin eye drops via complexation with cyclodextrins. Halim Mohamed MA; Mahmoud AA Curr Eye Res; 2011 Mar; 36(3):208-16. PubMed ID: 21275515 [TBL] [Abstract][Full Text] [Related]
12. Design of an anti-inflammatory composite nanosystem and evaluation of its potential for ocular drug delivery. Du Toit LC; Govender T; Carmichael T; Kumar P; Choonara YE; Pillay V J Pharm Sci; 2013 Aug; 102(8):2780-805. PubMed ID: 23828405 [TBL] [Abstract][Full Text] [Related]
13. Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. Calvo P; Vila-Jato JL; Alonso MJ Biomaterials; 1997 Oct; 18(19):1305-10. PubMed ID: 9307220 [TBL] [Abstract][Full Text] [Related]
14. Functionalized (poly(ɛ-caprolactone))₂-poly(ethylene glycol) nanoparticles with grafting nicotinic acid as drug carriers. Suksiriworapong J; Sripha K; Kreuter J; Junyaprasert VB Int J Pharm; 2012 Feb; 423(2):562-70. PubMed ID: 22155410 [TBL] [Abstract][Full Text] [Related]
15. Polycaprolactone Based Nanoparticles Loaded with Indomethacin for Anti-Inflammatory Therapy: From Preparation to Ex Vivo Study. Badri W; Miladi K; Robin S; Viennet C; Nazari QA; Agusti G; Fessi H; Elaissari A Pharm Res; 2017 Sep; 34(9):1773-1783. PubMed ID: 28527126 [TBL] [Abstract][Full Text] [Related]
16. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Nagai N; Ito Y; Okamoto N; Shimomura Y Toxicology; 2014 May; 319():53-62. PubMed ID: 24598350 [TBL] [Abstract][Full Text] [Related]
17. Influence of poly(DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Fawaz F; Bonini F; Guyot M; Lagueny AM; Fessi H; Devissaguet JP Pharm Res; 1993 May; 10(5):750-6. PubMed ID: 8321841 [TBL] [Abstract][Full Text] [Related]
18. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Losa C; Marchal-Heussler L; Orallo F; Vila Jato JL; Alonso MJ Pharm Res; 1993 Jan; 10(1):80-7. PubMed ID: 8094245 [TBL] [Abstract][Full Text] [Related]
19. Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. Katzer T; Chaves P; Bernardi A; Pohlmann A; Guterres SS; Ruver Beck RC J Microencapsul; 2014; 31(6):519-28. PubMed ID: 24697184 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of indomethacin nanocapsules. Andrieu V; Fessi H; Dubrasquet M; Devissaguet JP; Puisieux F; Benita S Drug Des Deliv; 1989 Jun; 4(4):295-302. PubMed ID: 2775449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]